Pelareorep

N/A

Report date: 2025/01/10 10:30:33

Base Information

Drug NamePelareorep
Drug Alias NameReovirus Serotype 3 - Dearing StrainReovirus antitumourReovirus anticancerRespiratory Enteric Orphan virusReovirus +[11] 
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionImmunostimulantsApoptosis stimulants
TargetsNot applicable
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursAnemia +[33] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOncolytics Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncolytics Biotech IncSafc Carlsbad IncUniversity Of Southern California +[7] 
Inactive CompaniesUniversity Of LeedsNorthwestern University
Active IndicationsMetastatic breast cancerAnemiaBrain Neoplasms +[16] 
Inactive IndicationsSolid tumoursProstatic NeoplasmsFallopian Tube Neoplasms +[17] 

Other Information

ATC CodeN/A
Related LinksWikipedia